| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | M-phase inducer phosphatase 2;3.1.3.48;Dual specificity phosphatase Cdc25B;CDC25B;CDC25HU2; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human CRYAA |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-CRYAA antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 23C19; isotype IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, ICC, IF (as provided in the source record). Boster Bio Anti-CRYAA Rabbit Monoclonal Antibody catalog # M01900-4. Tested in WB, ICC/IF applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: CRYAA (M-phase inducer phosphatase 2).
- Antibody format: Monoclonal; clone 23C19; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
CRYAA (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. ly dephosphorylates CDK1 and stimulates its kinase activity. The three isoforms seem to have a different level of activity. . Reported cellular localization context: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, spindle pole. Tissue expression notes (as provided): Widely expressed (PubMed:16044242). Highly expressed in heart and skeletal muscle (PubMed:12802337). Expressed at intermediate level in brain, spleen, kidney, liver, placenta, lung and peripheral blood leukocytes (PubMed:12802337). Weakly expressed in colon, thymus and small intestine (PubMed:12802337). .
Research relevance and current trends
- Research context keywords from the source record include: Cancer,Cell Biology,Cell Cycle,Epigenetics and Nuclear Signaling,Kinases/Phosphatases.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
Workflow ideas (metafield): Validate CRYAA antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect CRYAA expression by Western blot in cell or tissue lysates, Localize CRYAA by immunofluorescence/immunocytochemistry in cultured cells
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 17 kDa, 20 kDa; calculated MW: 64987 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 17 kDa, 20 kDa
- Cellular localization (provided): Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, spindle pole.
- Tissue details (provided): Widely expressed (PubMed:16044242). Highly expressed in heart and skeletal muscle (PubMed:12802337). Expressed at intermediate level in brain, spleen, kidney, liver, placenta, lung and peripheral blood leukocytes (PubMed:12802337). Weakly expressed in colon, thymus and small intestine (PubMed:12802337). .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
